Your Genes Aren't Your Destiny. They're Your Cost of Entry.

August 4, 2026 · 5min read · Rob Amoroso

Two lies get told about genetics.

The first is that your genes decide your future.

Thanks for reading Rob's HGF Substack! Subscribe for free to receive new posts and support my work.

The second is that they don’t really matter.

Both have cost people years.

Here’s what I’ve landed on instead. Your genes don’t decide where you can go. They decide what it costs you to get there.

Ask a better question

When most people open a DNA report, they’re looking for what’s wrong with them.

I get the instinct. It’s still the wrong question.

Try this one instead: what costs me more than it costs the person next to me?

That’s what most variants actually are. Not a diagnosis. A price.

Two people do the same work. Same training, same food, same effort. One gets there. One fights for every inch.

The easy read is that one of them wanted it more.

Sometimes that’s true. Often it isn’t, and what you’re actually looking at is one person paying more for the identical result, with no way for anyone watching to see it. Including them.

Your DNA is a price list, not a report card.

So what’s actually getting expensive?

Here’s what people miss. Genes don’t lower your capacity directly.

They raise the cost of maintaining it.

When a pathway gets expensive enough, it eats capacity just to produce the same output you always did. Eventually it becomes the bottleneck. Not because it’s broken. Because it’s carrying more than it was built for, and it’s been doing that quietly for a long time.

One real example

COMT is an enzyme that clears the signals behind focus and stress response out of your brain. Some people clear fast. Some clear slow.

Which one is better?

Neither. They’re two different systems with two different bills.

Slow clearance means those signals stick around. On a normal week that often looks like great focus. The person who locks in and doesn’t come up for air.

Now add a launch, a newborn, six months of bad sleep.

Same person. Same pathway. And the thing that was an edge becomes the problem. They were already running full, so they tip sooner. Wired, hot, can’t shut off at night.

Fast clearance flips it. Focus takes more effort on an ordinary Tuesday, but there’s more room before they tip when life gets loud.

So what changed for that first person?

Not their genome. Their demand.

The same variant can cost nothing in one season and a fortune in the next.

One warning while we’re here. You may have seen this sold as warrior versus worrier. Leave that alone. The enzyme science is solid. The personality story built on top of it is a cartoon, and it’s what happens when someone takes real biology and dresses it up for an audience.

Why we don’t start with your genes

We start somewhere else: where is your capacity leaking right now?

Your body doesn’t care how many variants you carry. It cares which pathway is eating the most capacity today.

A slow pathway that never gets overloaded may never matter to you.

A common variant sitting inside your highest-demand system might explain years of struggle you’ve been blaming on yourself.

Genes are one layer of the story. Capacity is the story.

Where the industry gets it backwards

Most reports spend all their energy telling you what you have.

That’s the least interesting part.

The real question is whether that variant is limiting you right now. You can’t answer it from the genome alone. You need your symptoms, your labs, your sleep, your training, what you’re carrying at home, what season you’re actually in.

Not every variant matters. Not every pathway is under pressure. Not every recommendation belongs on your protocol.

Context determines cost. Cost determines priority.

Can it be fixed?

Sometimes, substantially.

Sometimes not at all.

Both are worth knowing. If the cost can come down, we bring it down. If it can’t, we stop fighting reality and build the route around it.

Either way you stop guessing, and guessing is expensive.

What we’ll tell you, and what we won’t

This is the part most companies skip, and it’s what I’d judge them on.

We only act on what was actually measured. Some methods read a position directly. Others estimate it from population averages. Fine for research, poor basis for telling one specific person what to take. If we act on it, it was directly read.

We tell you what’s proven and what’s reasoned. You just watched me do it with COMT. The enzyme science is established. The personality story isn’t, and I said so rather than let the better story carry the weaker one.

We don’t confuse genetics with diagnosis. Some findings belong with your physician, not your coach. When that happens we say so and hand it over with the data attached.

Truth is worth more to you than certainty.

“Should I even look?”

People ask me that. What if I find something bad.

Fair question. But consider the other side.

Most people I talk to have spent years quietly blaming themselves for things they couldn’t explain. Low energy. Brain fog by two o’clock. Working twice as hard as the person beside them just to stay level.

What happens when you finally find the mechanism underneath that?

In my experience, relief.

Because the question changes. Not “what’s wrong with me,” which never had a useful answer.

But “what has been costing me capacity all this time?”

Only one of those leads anywhere.

The line worth keeping

We’re not trying to predict your future. We’re trying to explain your present.

Every unnecessary cost is capacity that isn’t available for the things you actually care about.

A price list is not a scoreboard. It describes conditions, not worth. Two people can inherit completely different costs and both build something worth building. What changes is the route.

The goal was never to change your genes.

The goal is to stop paying what you don’t have to pay, so the life you were made for costs you less to carry.